(+49) 176 69639585
(+49) 176 69639585
Connecting German and European pharmaceutical companies with potential partners in Argentina.
Argentina offers a developed pharmaceutical manufacturing base, biotechnology capabilities, clinical research expertise and a network of scientific institutions. For German and EU companies, these capabilities may create opportunities for contract manufacturing, research cooperation, strategic sourcing and technology partnerships.
Argentina Business Network helps companies explore these opportunities, identify potential partners and structure the first steps towards commercially viable cooperation.
Define your requirements and identify the most relevant opportunities for your organisation.
Discuss Your ProjectArgentina has a long history of pharmaceutical manufacturing and scientific research. Its ecosystem includes pharmaceutical laboratories, biotechnology companies, research institutions, medical universities and clinical research organisations.
Relevant areas of activity include:
Generic and branded medicines, solid and liquid dosage forms, sterile products and selected active pharmaceutical ingredients (APIs).
Research and development involving vaccines, recombinant proteins, biosimilars, diagnostics and other biological products.
Clinical research services, medical technology, laboratory capabilities and cooperation between industry and research institutions.
Temperature-controlled transport, specialised warehousing, product traceability and distribution services, subject to verification of individual providers and facilities.
Capabilities vary by company, product category and facility. Regulatory status, quality systems, export eligibility and technical capacity must therefore be assessed at partner level rather than assumed for the sector as a whole.
Potential areas for cooperation include tablets, capsules, controlled-release formulations, sterile liquids, lyophilised products, selected APIs and finished dosage forms for prescription and over-the-counter medicines.
Possible projects may involve contract manufacturing, production transfers, packaging, labelling or the development of additional supply sources. Each opportunity requires a product-specific assessment of capacity, quality, intellectual property and regulatory requirements.
Argentina’s scientific and biotechnology ecosystem may offer opportunities for cooperation in recombinant proteins, vaccines, diagnostics, biosimilars, laboratory technologies and health-related data applications.
Potential partners may include biotechnology companies, research centres, universities and specialist technology providers.
Clinical research organisations, hospitals, investigators and research institutions may support international studies, depending on their experience, capacity, approvals and the requirements of the specific protocol.
Possible areas include clinical trials, bioequivalence studies, epidemiological research and collaborative studies with academic or biotechnology partners.
Specialised logistics can be relevant for products requiring controlled temperature, documented handling and traceability. Companies should verify the actual scope of each provider’s licences, certifications, facilities and quality procedures before appointing them.
Companies may explore Argentine manufacturers for selected APIs, intermediates, finished dosage forms, sterile products, biopharmaceuticals or secondary packaging.
Potential benefits include access to additional production capacity, specialised technical capabilities and alternative supply arrangements. Commercial attractiveness depends on product specifications, batch sizes, transfer costs, quality requirements, tariffs, logistics and regulatory approvals.
Key checks: GMP status and inspection history, technical transfer readiness, analytical methods, batch documentation, capacity, change control, data integrity and product-specific market authorisations.
German and European sponsors may investigate partnerships with clinical research organisations, medical institutions, investigators and research centres in Argentina.
Possible project types include Phase I–IV studies, bioequivalence studies, real-world evidence projects and epidemiological research, where appropriate and authorised.
Key checks: relevant study experience, ethics committee approvals, applicable regulatory authorisations, informed consent, data protection, monitoring arrangements, pharmacovigilance and compliance with the requirements of the sponsor’s target markets.
Procurement teams may investigate Argentine suppliers of pharmaceutical ingredients, formulated products, laboratory consumables, biotechnology reagents, medical devices and diagnostic technologies.
Supplier diversification can be useful when supported by a robust qualification process. It does not automatically reduce risk or cost: the business case must account for quality, supply continuity, currency exposure, import requirements and total landed cost.
Key checks: product specifications, quality documentation, manufacturing origin, traceability, supply capacity, intellectual property, export experience and independent audit requirements.
The appropriate model depends on the product, target market, development stage, intellectual-property position and the resources available to both partners.
Argentina has established academic and research institutions and professionals working across chemistry, pharmacy, biology, biotechnology, clinical research and medical technology.
The pharmaceutical and biotechnology ecosystem offers a range of potential manufacturing, research and sourcing partners. Suitability must be confirmed for each individual project.
Argentine partners may complement European expertise in manufacturing, research, product development or regional distribution. The best opportunities are those where capabilities, commercial objectives and quality expectations are clearly aligned.
Qualified alternative suppliers can support a broader sourcing strategy. Any diversification decision should include a realistic assessment of logistics, regulatory approval, geopolitical exposure and continuity of supply.
These are potential advantages, not guaranteed outcomes. Cost savings, time-to-market improvements and export opportunities must be validated for the specific product and business model.
Pharmaceutical and life-sciences cooperation requires more than identifying a technically capable partner. Regulatory acceptability and quality assurance must be assessed before commercial commitments are made.
Important: Argentine authorisation or certification does not automatically establish eligibility for the EU market. Requirements depend on the product, facility, intended use and applicable regulatory pathway. Independent technical audits and specialist regulatory, legal or scientific advice may be necessary.
Argentina Business Network supports the business-development and coordination side of German–Argentine cooperation. Our role is to help clarify the project, identify relevant counterparties and organise the initial dialogue.
Clarify the product category, technical specifications, target market, volumes, quality expectations and commercial objectives.
Develop a focused search for manufacturers, CROs, suppliers, research institutions or logistics providers whose stated capabilities appear relevant.
Support introductions, bilingual communication, information exchange and clarification of the initial scope of cooperation.
Help organise follow-up discussions, information requests, preliminary commercial assessments and a practical project roadmap.
ABN’s partner identification and coordination support is not a substitute for independent supplier audits, regulatory assessments, clinical oversight, legal advice, tax advice or financial due diligence. These services should be provided by appropriately qualified specialists where required.
A staged approach helps companies identify critical gaps early and avoid making commercial commitments before the relevant technical and regulatory questions have been resolved.
Potentially, but eligibility must be assessed for each product and manufacturing site. Applicable EU authorisations, quality requirements, import procedures and release arrangements must be confirmed before supply begins.
ABN can help identify potential counterparties and coordinate initial discussions. The availability and suitability of partners depend on the specific product, technical requirements, volumes and qualification criteria.
No. The scope, issuing authority, inspection status, manufacturing activity and destination-market requirements must be checked. A certificate alone should not be treated as a universal guarantee of regulatory acceptability.
Clinical research may be possible where the relevant protocol, institutions and service providers meet applicable regulatory, ethics, data-protection and sponsor requirements. The feasibility of each study needs a specific assessment.
ABN supports partner identification and business coordination. Formal audits, regulatory submissions, approvals and specialist legal or scientific assessments must be handled by the appropriate qualified parties.
Whether you are looking for a contract manufacturing partner, a clinical research organisation, a qualified supplier or a biotechnology cooperation opportunity, Argentina Business Network can help you define the search and connect with potential counterparts.
Share your requirements, target market and preferred cooperation model so that the next steps can be focused on your business objectives.
Contact Argentina Business NetworkInitial discussions do not constitute regulatory, legal, medical or investment advice. Any cooperation remains subject to partner qualification, applicable approvals and a mutually agreed commercial framework.
